Sanjay M. Udoshi MD
Healthcare organizations sit on vast reserves of clinical data. Electronic health records, claims databases, laboratory information systems, imaging archives, and patient-reported outcome repositories collectively represent one of the richest sources of observational data in existence. Yet the translation of this raw data into actionable clinical knowledge — knowledge that changes practice and improves outcomes — remains one of the most persistent challenges in modern medicine.
The gap between data and knowledge is not primarily a technology problem. It is a methodology problem, a workflow problem, and an organizational problem. Bridging it requires a systematic approach that begins with data standardization, progresses through rigorous analytical methods, and culminates in decision support tools that deliver the right information to the right clinician at the right moment.
Most health systems today operate at the lower end of the analytics maturity spectrum. They produce descriptive analytics — reports and dashboards that tell you what happened. Census counts, length of stay averages, readmission rates, quality measure compliance percentages. These reports are essential for operational management and regulatory reporting, but they are fundamentally backward-looking. They describe the past; they do not illuminate the future.
The next level — diagnostic analytics — begins to answer why something happened. Why did readmissions spike last quarter? Why are certain patient populations experiencing worse outcomes? Diagnostic analytics requires the ability to segment data, identify correlations, and test hypotheses. It demands higher-quality data and more sophisticated analytical methods than simple descriptive reporting.
Predictive analytics represents a further leap. Rather than explaining the past, predictive models estimate the probability of future events. Which patients are most likely to be readmitted within 30 days? Which surgical patients are at elevated risk of post-operative complications? Which chronic disease patients are trending toward clinical deterioration? Predictive analytics transforms data from a mirror into a window.
At the highest level of the spectrum sits prescriptive analytics — systems that not only predict what will happen but recommend what should be done about it. A prescriptive system might identify a patient at high risk of sepsis and simultaneously recommend a specific diagnostic workup and treatment protocol based on the patient's individual characteristics. This is the domain of true clinical decision support.
One of the most important and underappreciated disciplines in clinical analytics is phenotyping — the precise definition of patient cohorts using computable criteria. A phenotype is essentially a recipe for identifying patients who share a specific clinical characteristic or combination of characteristics.
Phenotyping sounds simple but is in practice extraordinarily nuanced. Consider the task of identifying patients with Type 2 diabetes. Should the phenotype be based on diagnosis codes alone? If so, which codes? ICD-10-CM E11.x covers Type 2 diabetes, but what about patients coded with E13.x (other specified diabetes) or those with no diabetes code but an HbA1c above 6.5% and a prescription for metformin? Each definitional choice affects which patients are included in a cohort, which in turn affects the validity of any analysis performed on that cohort.
The OHDSI community has invested heavily in developing standardized, validated phenotype definitions that can be shared across institutions. This work is foundational. Without reliable phenotypes, every downstream analysis — from prevalence estimation to treatment effectiveness evaluation — rests on uncertain ground. The rigor of a phenotype definition is, in many ways, the single most important determinant of the quality of a clinical study.
Machine learning brings a set of capabilities to clinical analytics that traditional statistical methods cannot match. Where classical regression models require the analyst to specify the relationships between variables, machine learning algorithms can discover complex, non-linear patterns in high-dimensional data. This makes them particularly well-suited to clinical problems where the relationships between predictors and outcomes are complex and poorly understood.
Gradient-boosted decision trees, random forests, and deep learning models have demonstrated strong performance across a range of clinical prediction tasks — sepsis early warning, mortality risk stratification, disease progression modeling, and medication response prediction. In many cases, these models outperform traditional risk scores that have been in clinical use for decades.
However, the deployment of machine learning in clinical settings introduces challenges that do not arise in other domains. Explainability is paramount — a clinician cannot responsibly act on a prediction without understanding, at least in general terms, why the model produced that prediction. Regulatory requirements around model transparency, bias detection, and performance monitoring add layers of governance that must be built into the development lifecycle from the outset. And the stakes of errors — false positives that lead to unnecessary interventions, false negatives that miss critical deterioration — are qualitatively different from errors in consumer recommendation systems.
One of the most powerful applications of advanced analytics in healthcare is the network-based observational study. Rather than conducting analyses within a single institution's data, network studies execute standardized analytical protocols across multiple sites simultaneously, combining results while keeping individual patient data within each institution's governance boundaries.
The OHDSI network exemplifies this approach. With data partners spanning academic medical centers, integrated delivery networks, claims databases, and national health systems across dozens of countries, OHDSI enables studies at a scale and diversity that no single institution could achieve. Network studies have generated evidence on the comparative effectiveness of antihypertensive medications, the safety profiles of novel therapeutics, the epidemiology of rare diseases, and the real-world impact of clinical guidelines.
The key enabler of network-based research is data standardization. Because all participating sites map their data to the OMOP Common Data Model, analytical code written once can be executed identically across the entire network. This reproducibility is both a scientific strength and an efficiency gain — it eliminates the need to negotiate data sharing agreements, re-engineer analyses for different data structures, or reconcile incompatible variable definitions.
The ultimate purpose of advanced analytics is to inform clinical decisions. But the history of clinical decision support (CDS) in healthcare is largely a history of failure — not because the underlying analytics were wrong, but because the tools were poorly designed, badly integrated, and insufficiently attentive to the realities of clinical workflow.
Effective CDS must satisfy several criteria simultaneously. It must be timely — delivering information at the moment of decision, not after the fact. It must be relevant — filtering the vast universe of potentially useful information down to what matters for this specific patient in this specific context. It must be actionable — providing not just information but clear options for what to do with it. And it must be non-disruptive — integrating into the clinician's existing workflow rather than requiring additional clicks, screens, or cognitive effort.
These requirements are demanding, and few CDS implementations satisfy all of them. But the stakes are high enough to justify the investment. Effective decision support can reduce diagnostic errors, improve guideline adherence, prevent adverse drug events, and close gaps in preventive care. When designed well, CDS represents the bridge between analytical insight and improved patient outcomes.
At Acumenus, we view knowledge generation as a pipeline — a systematic process that begins with raw data and ends with clinical action. Each stage of the pipeline requires specific investments:
Each stage depends on the stages before it. A brilliant machine learning model built on unstandardized data will produce unreliable results. A sophisticated CDS tool that delivers information at the wrong moment will be ignored. The pipeline must be built end to end, with attention to quality and integration at every stage.
The transformation of healthcare data into clinical knowledge is not a technology purchase. It is an organizational commitment — to data quality, to methodological rigor, to interdisciplinary collaboration, and to the relentless pursuit of better outcomes for every patient. The tools are available. The standards exist. The evidence base for data-driven quality improvement is strong. What remains is the will to build the pipeline, invest in the foundations, and sustain the effort over the years required to realize the full potential of advanced analytics in healthcare.
Dr. Udoshi is Medical Director of Informatics at Acumenus Data Sciences and has authored more than 60 peer-reviewed publications in clinical informatics and health IT.
More perspectives from the Acumenus team.